Alan Urban
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Alan Urban
Alan Urban is recorded as CFO at GT Biopharma, Inc. (GTBP). Earlier roles on record: CFO at Research Solutions, Inc. (RSSS) until October 4, 2021. GT Biopharma, Inc. reported in an 8-K filed May 4, 2023 that Alan Urban resigned as member of the Board of Directors, effective May 1, 2023. The proxy statement of GT Biopharma, Inc. reports total compensation of $739,310 for Alan Urban in fiscal 2025, including a base salary of $393,750. Disclosed compensation is on record for 2 fiscal years. Alan Urban has spoken on 3 earnings calls across 1 company, most recently for Research Solutions, Inc. on June 30, 2021.
“On May 1, 2023 Alan Urban resigned as a member of the Registrant's Board of Directors (the "Board").”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
-
Start not stated–2021-10-04
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at GT Biopharma, Inc.
Other people whose current roles at this company are on record from its filings.
- Anthony Cataldo CEO
- Dr. Gregory Berk CEO
- Michael Breen CEO, Board Member
- Bruce Wendel Chairman
- Alan L. Urban CFO, Board Member
- Dr. Gavin Choy CFO
- Michael Handelman CFO
- Andrew Ritter Board Member
- Charles J. Casamento Board Member
- David C. Mun-Gavin Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | GT Biopharma, Inc. (GTBP) | Chief Financial Officer | $393,750 | $739,310 |
| 2024 | GT Biopharma, Inc. (GTBP) | Chief Financial Officer | $218,750 | $377,782 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.